Michael Freeman
Stock Analyst at Raymond James
(0)
# 4337
Out of 5,370 analysts
6
Total ratings
0.00%
Success rate
-6.06%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
WVE WAVE Life Sciences | Assumes: Outperform | 14 | 6.84 | 104.68% | 1 | Jun 11, 2025 | |
TECX Tectonic Therapeutic | Reinstates: Outperform | 76 | 21.35 | 255.97% | 1 | Jun 11, 2025 | |
DYN Dyne Therapeutics | Assumes: Outperform | 37 | 13.81 | 167.92% | 1 | Jun 11, 2025 | |
IRON Disc Medicine | Reinstates: Strong Buy | 89 | 51.94 | 71.35% | 1 | Jun 11, 2025 | |
RNA Avidity Biosciences | Initiates Coverage On: Strong Buy | 65 | 29.84 | 117.83% | 1 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 8 | 5.91 | 35.36% | 1 | Jul 10, 2024 |